| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3297315 | Gastroenterology | 2009 | 11 Pages |
Abstract
The greater efficacy of high-dose celecoxib, compared with the low-dose, in preventing colorectal adenoma appears confined to individuals with slow metabolizer (CYP2C9*3) genotypes. Genetic variability influences susceptibility to the potential benefits and hazards of celecoxib.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Andrew T. Chan, Ann G. Zauber, Meier Hsu, Aurora Breazna, David J. Hunter, Rebecca B. Rosenstein, Craig J. Eagle, Ernest T. Hawk, Monica M.. Bertagnolli,